Paul H Klingenstein Net Worth

The estimated Net Worth of Paul H Klingenstein is at least $33.2 Tisíc dollars as of 29 July 2019. Paul Klingenstein owns over 25,862 units of Conatus Pharmaceuticals stock worth over $33,223 and over the last 13 years Paul sold CNAT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Klingenstein CNAT stock SEC Form 4 insiders trading

Paul has made over 3 trades of the Conatus Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently Paul exercised 25,862 units of CNAT stock worth $7,500 on 29 July 2019.

The largest trade Paul's ever made was buying 399,291 units of Conatus Pharmaceuticals stock on 21 November 2011 worth over $5,190,783. On average, Paul trades about 38,041 units every 200 days since 2011. As of 29 July 2019 Paul still owns at least 59,327 units of Conatus Pharmaceuticals stock.

You can see the complete history of Paul Klingenstein stock trades at the bottom of the page.

What's Paul Klingenstein's mailing address?

Paul's mailing address filed with the SEC is C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER, CO, 80301.

Insiders trading at Conatus Pharmaceuticals

Over the last 11 years, insiders at Conatus Pharmaceuticals have traded over $0 worth of Conatus Pharmaceuticals stock and bought 1,570,135 units worth $17,229,485 . The most active insiders traders include Shahzad Malik, Paul H Klingenstein a Preston Klassen. On average, Conatus Pharmaceuticals executives and independent directors trade stock every 83 days with the average trade being worth of $47,160. The most recent stock trade was executed by Steven J Mento on 4 May 2018, trading 60,000 units of CNAT stock currently worth $59,400.

What does Conatus Pharmaceuticals do?

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.

Complete history of Paul Klingenstein stock trades at Clovis Oncology Inc a Conatus Pharmaceuticals

Conatus Pharmaceuticals executives and stock owners

Conatus Pharmaceuticals executives and other stock owners filed with the SEC include:

• Steven Mento,
  Director
• Daniel Kisner,
  Independent Director
• Hayden Yizhuo Zhang,
  Director
• Brian Satz,
  Director
• Jonathan Jackson,
  Director
• Stephen Chang,
  Director
• Thomas Hubka,
  Director of Business Operations, Corporate Secretary
• Martin Latterich,
  Vice President - Technical Operations
• Edward Smith,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• Daniel Ripley,
  Senior Vice President - Business Development, Program and Alliance Management
• Moya Daniels,
  Executive Vice President and Head of Regulatory, Quality and Clinical Operations
• Susan Knudson,
  Chief Financial Officer, Executive Vice President
• Gail Naughton,
  Founder, Chief Scientific Officer, Chief Business Officer
• Richard Pascoe,
  President, Chief Executive Officer, Director
• David Crean,
  Chairman of the Board
• William R Larue,
  Director
• Charles Cashion,
  SVP, Finance, CFO and Sec.
• Shahzad Malik,
  Director
• Alfred P. Spada,
  EVP, R&D and CSO
• David T Hagerty,
  EVP, Clinical Development
• Wart Harold Van,
  Director
• James Paul Scopa,
  Director
• Preston Klassen,
  Director
• David F Hale,
  Director
• Louis P Lacasse,
  Director
• Kathleen D. Scott,
  Director
• Keith W Marshall,
  EVP, COO & CFO
• Michelle L Vandertie,
  Vice President, Finance
• Venture Partners Llp Advent,
  10% owner
• Luke Foley Todd Gadicke Ans...,
  
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Gp Iii, L.L.C.Aberdare Vent...,
  
• Paul H Klingenstein,
  Director
• Marc Olivier Perret,
  Director
• Gilde Healthcare Ii U.A. Co...,
  10% owner
• Gary C. Burgess,
  Sr. VP, Clin. Res. & CMO